{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:54:33Z","timestamp":1791305673978,"version":"4.3.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01025-8","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:14:43Z","timestamp":1791303283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine in Adults of Hispanic or Latino Ethnicity: Post Hoc Analysis of Three Randomized, Placebo-Controlled Trials"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7772-6146","authenticated-orcid":false,"given":"Julio R.","family":"Vieira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9663-929X","authenticated-orcid":false,"given":"Meghan","family":"Fajardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6476-3558","authenticated-orcid":false,"given":"Michael T.","family":"Sellix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"1025_CR1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1212\/WNL.0000000000012261","volume":"97","author":"J Kiarashi","year":"2021","unstructured":"Kiarashi J, VanderPluym J, Szperka CL, et al. Factors associated with, and mitigation strategies for, health care disparities faced by patients with headache disorders. Neurology. 2021;97:280\u20139.","journal-title":"Neurology"},{"key":"1025_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/head.13018","volume":"57","author":"NM Robbins","year":"2017","unstructured":"Robbins NM, Bernat JL. Minority representation in migraine treatment trials. Headache. 2017;57:525\u201333.","journal-title":"Headache"},{"key":"1025_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/head.14024","volume":"61","author":"R Burch","year":"2021","unstructured":"Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021;61:60\u20138.","journal-title":"Headache"},{"key":"1025_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1526-4610.2005.05024.x","volume":"45","author":"LE Morillo","year":"2005","unstructured":"Morillo LE, Alarcon F, Aranaga N, et al. Prevalence of migraine in Latin America. Headache. 2005;45:106\u201317.","journal-title":"Headache"},{"key":"1025_CR5","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1046\/j.1526-4610.2002.02206.x","volume":"42","author":"CA Molgaard","year":"2002","unstructured":"Molgaard CA, Rothrock J, Stang PE, Golbeck AL. Prevalence of migraine among Mexican Americans in San Diego, California: survey 1. Headache. 2002;42:878\u201382.","journal-title":"Headache"},{"key":"1025_CR6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213351","volume":"104","author":"D Kellier","year":"2025","unstructured":"Kellier D, Anto MM, Hall M, et al. Association of race and ethnicity with emergency room rate of migraine diagnosis, testing, and management in children with headache. Neurology. 2025;104:e213351.","journal-title":"Neurology"},{"key":"1025_CR7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/head.12506","volume":"55","author":"S Loder","year":"2015","unstructured":"Loder S, Sheikh HU, Loder E. The prevalence, burden, and treatment of severe, frequent, and migraine headaches in US minority populations: statistics from National Survey studies. Headache. 2015;55:214\u201328.","journal-title":"Headache"},{"key":"1025_CR8","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1212\/WNL.0000000000004025","volume":"88","author":"A Saadi","year":"2017","unstructured":"Saadi A, Himmelstein DU, Woolhandler S, Mejia NI. Racial disparities in neurologic health care access and utilization in the United States. Neurology. 2017;88:2268\u201375.","journal-title":"Neurology"},{"key":"1025_CR9","unstructured":"Pfizer Inc. Nurtec ODT (rimegepant) prescribing information. 2020. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19036. Accessed Sept 2025."},{"key":"1025_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40263-023-00988-8","volume":"37","author":"HA Blair","year":"2023","unstructured":"Blair HA. Rimegepant: a review in the acute treatment and preventive treatment of migraine. CNS Drugs. 2023;37:255\u201365.","journal-title":"CNS Drugs"},{"key":"1025_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase\u00a03, double-blind, placebo-controlled trial. Lancet. 2019;394:737\u201345.","journal-title":"Lancet"},{"key":"1025_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381:142\u20139.","journal-title":"N Engl J Med"},{"key":"1025_CR13","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.2147\/JPR.S453806","volume":"17","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, Thiry A, Morris BA, Croop R. Efficacy and safety of rimegepant 75\u00a0mg oral tablet, a CGRP receptor antagonist, for the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. J Pain Res. 2024;17:2431\u201341.","journal-title":"J Pain Res"},{"key":"1025_CR14","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629\u2013808.","DOI":"10.1177\/0333102413485658"},{"key":"1025_CR15","doi-asserted-by":"publisher","first-page":"333102423121950","DOI":"10.1177\/03331024231219505","volume":"44","author":"R Croop","year":"2024","unstructured":"Croop R, Bhardwaj R, Anderson MS, et al. Bioequivalence of rimegepant, a small molecule CGRP receptor antagonist, administered as an oral tablet, a sublingual orally disintegrating tablet, and a supralingual orally disintegrating tablet: two phase\u00a01 randomized studies in healthy adults. Cephalalgia. 2024;44:3331024231219505.","journal-title":"Cephalalgia"},{"key":"1025_CR16","first-page":"1","volume":"94","author":"VJ Burroughs","year":"2002","unstructured":"Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc. 2002;94:1\u201326.","journal-title":"J Natl Med Assoc"},{"key":"1025_CR17","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.107.704023","volume":"118","author":"JA Johnson","year":"2008","unstructured":"Johnson JA. Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation. 2008;118:1383\u201393.","journal-title":"Circulation"},{"key":"1025_CR18","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/ehjcvp\/pvac040","volume":"8","author":"J Tamargo","year":"2022","unstructured":"Tamargo J, Kaski JC, Kimura T, et al. Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events. Eur Heart J Cardiovasc Pharmacother. 2022;8:738\u201351.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"1025_CR19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/ng.856","volume":"43","author":"DI Chasman","year":"2011","unstructured":"Chasman DI, Schurks M, Anttila V, et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet. 2011;43:695\u20138.","journal-title":"Nat Genet"},{"key":"1025_CR20","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/cts.13513","volume":"16","author":"J Bottern","year":"2023","unstructured":"Bottern J, Stage TB, Dunvald AD. Sex, racial, and ethnic diversity in clinical trials. Clin Transl Sci. 2023;16:937\u201345.","journal-title":"Clin Transl Sci"},{"key":"1025_CR21","unstructured":"National Academies of Sciences, Engineering, and Medicine; Policy and Global Affairs; Committee on Women in Science, Engineering, and Medicine; Committee on Improving the Representation of Women and Underrepresented Minorities in Clinical Trials and Research; Bibbins-Domingo K, Helman A, editors. Improving representation in clinical trials and research: building research equity for women and underrepresented groups. 2022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK584396\/. Accessed July 2026."},{"key":"1025_CR22","doi-asserted-by":"crossref","unstructured":"Turner BE, Steinberg JR, Weeks BT, Rodriguez F, Cullen MR. Race\/ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg Health Am. 2022;11:100252.","DOI":"10.1016\/j.lana.2022.100252"},{"key":"1025_CR23","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1474-4422(23)00126-6","volume":"22","author":"S Yu","year":"2023","unstructured":"Yu S, Kim BK, Guo A, et al. Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase\u00a03, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2023;22:476\u201384.","journal-title":"Lancet Neurol"},{"key":"1025_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14737175.2026.2621879","volume":"26","author":"L Pellesi","year":"2026","unstructured":"Pellesi L, Scuteri D, Martelletti P. Positioning rimegepant in migraine prophylaxis: updated evidence and emerging perspectives. Expert Rev Neurother. 2026;26:315\u201323.","journal-title":"Expert Rev Neurother"},{"key":"1025_CR25","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/03007995.2022.2057152","volume":"38","author":"L Charleston","year":"2022","unstructured":"Charleston L, Savage-Edwards B, Bragg SM, Baygani SK, Dennehy EB. Migraine history and response to lasmiditan across racial and ethnic groups. Curr Med Res Opin. 2022;38:721\u201330.","journal-title":"Curr Med Res Opin"},{"key":"1025_CR26","doi-asserted-by":"publisher","first-page":"333102423121839","DOI":"10.1177\/03331024231218392","volume":"43","author":"H Basedau","year":"2023","unstructured":"Basedau H, Ornello R, Matteis E, et al. Placebo and nocebo in the treatment of migraine: how much does real world effectiveness depend on contextual effects? Cephalalgia. 2023;43:3331024231218392.","journal-title":"Cephalalgia"},{"key":"1025_CR27","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1136\/medethics-2018-104811","volume":"44","author":"P Friesen","year":"2018","unstructured":"Friesen P, Blease C. Placebo effects and racial and ethnic health disparities: an unjust and underexplored connection. J Med Ethics. 2018;44:774\u201381.","journal-title":"J Med Ethics"},{"key":"1025_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1726-4901(09)70300-4","volume":"70","author":"SJ Wang","year":"2007","unstructured":"Wang SJ, Fuh JL, Wu ZA. Intranasal sumatriptan study with high placebo response in Taiwanese patients with migraine. J Chin Med Assoc. 2007;70:39\u201346.","journal-title":"J Chin Med Assoc"},{"key":"1025_CR29","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/j.1526-4610.2006.00453.x","volume":"46","author":"RA Nicholson","year":"2006","unstructured":"Nicholson RA, Rooney M, Vo K, O\u2019Laughlin E, Gordon M. Migraine care among different ethnicities: do disparities exist? Headache. 2006;46:754\u201365.","journal-title":"Headache"},{"key":"1025_CR30","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/j.pain.0000000000000731","volume":"158","author":"HJ Kim","year":"2017","unstructured":"Kim HJ, Yang GS, Greenspan JD, et al. Racial and ethnic differences in experimental pain sensitivity: systematic review and meta-analysis. Pain. 2017;158:194\u2013211.","journal-title":"Pain"},{"key":"1025_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/08870446.2013.830721","volume":"29","author":"C Stetler","year":"2014","unstructured":"Stetler C. Adherence, expectations and the placebo response: why is good adherence to an inert treatment beneficial? Psychol Health. 2014;29:127\u201340.","journal-title":"Psychol Health"},{"key":"1025_CR32","doi-asserted-by":"publisher","first-page":"9919773","DOI":"10.1155\/2021\/9919773","volume":"2021","author":"X Xu","year":"2021","unstructured":"Xu X, Ji Q, Shen M. Patient preferences and values in decision making for migraines: a systematic literature review. Pain Res Manag. 2021;2021:9919773.","journal-title":"Pain Res Manag"},{"key":"1025_CR33","doi-asserted-by":"publisher","first-page":"333102424123294","DOI":"10.1177\/03331024241232944","volume":"44","author":"R Croop","year":"2024","unstructured":"Croop R, Berman G, Kudrow D, et al. A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia. 2024;44:3331024241232944.","journal-title":"Cephalalgia"},{"key":"1025_CR34","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2147\/JPR.S456006","volume":"17","author":"T Fullerton","year":"2024","unstructured":"Fullerton T, Pixton G. Long-term use of rimegepant 75\u00a0mg for the acute treatment of migraine is associated with a reduction in the utilization of select analgesics and antiemetics. J Pain Res. 2024;17:1751\u201360.","journal-title":"J Pain Res"},{"key":"1025_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01378-5","volume":"23","author":"K Johnston","year":"2022","unstructured":"Johnston K, Harris L, Powell L, et al. Monthly migraine days, tablet utilization, and quality of life associated with rimegepant\u2014post hoc results from an open label safety study (BHV3000-201). J Headache Pain. 2022;23:10.","journal-title":"J Headache Pain"},{"key":"1025_CR36","doi-asserted-by":"publisher","first-page":"251581632210755","DOI":"10.1177\/25158163221075596","volume":"5","author":"G L\u2019Italien","year":"2022","unstructured":"L\u2019Italien G, Popoff E, Johnston K, et al. Rimegepant 75\u00a0mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: results from a long-term, open-label study. Cephalalgia Rep. 2022;5:25158163221075596.","journal-title":"Cephalalgia Rep"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01025-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01025-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01025-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:14:46Z","timestamp":1791303286000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01025-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":36,"alternative-id":["1025"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01025-8","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"8 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Julio Ricardo Vieira provided consulting to AbbVie, Alpha Sights Ltd, Amneal Pharmaceutics, Biodelivery Sciences International Inc, Impel Pharmaceutics Inc, Lundbeck, Pfizer, Slingshot Insights Inc, Tegus by AlphaSense, Theranica, Third Bridge and Guidepoint Global. Meghan Fajardo, Chandra Abbott, and Michael T. Sellix are employees of Pfizer and hold stock\/options. Jessica Li is affiliated with Pfizer.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Each trial was conducted in accordance with International Conference on Harmonization Good Clinical Practice guidelines, the principles of the Declaration of Helsinki, and all applicable local regulations. The protocols were approved by an independent ethics committee or institutional review board at each center. For NCT03461757, the protocol was approved by Advarra Institutional Review Board (Columbia, MD, USA). For NCT03235479 and NCT03237845, the protocol was approved by Schulman Associates Institutional Review Board, Inc. (Cincinnati, OH, USA). All patients provided written informed consent for participation in each study.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}